论文部分内容阅读
目的:探讨替米沙坦对2型糖尿病大鼠心肌保护作用及其细胞因子机制。方法:尾静脉注射链脲佐菌素(STZ)复制糖尿病大鼠(DM)模型。正常对照10只(C组),糖尿病模型12只不喂替米沙坦(D组),12只喂替米沙坦(T组)。12周末检测心功能及电镜观察心肌超微结构,western blot方法检测心肌HGF含量。结果:三组比较,LVSP和+dp/dtmax均无差异。与C组比较,D组及T组LVEDP升高(P<0.01),-dp/dtmax降低(P<0.05),HGF升高(P<0.01);与D组比较,T组LVEDP降低(P<0.01),-dp/dtmax升高(P<0.05),HGF升高(P<0.01)。结论:替米沙坦保护糖尿病大鼠心肌,可能与升高心肌HGF有关。
Objective: To investigate the myocardial protective effect of telmisartan on type 2 diabetic rats and its cytokine mechanism. Methods: Diabetic rats (DM) were induced by streptozotocin (STZ) into the tail vein. Ten rats in normal control group (C group) and 12 diabetic rats were given telmisartan (group D) and 12 rats were fed telmisartan (group T). At the end of 12th week, heart function was detected and the ultrastructure of myocardium was observed by electron microscope. The content of HGF in myocardium was detected by western blot. Results: There was no difference between LVSP and + dp / dtmax in three groups. Compared with group C, LVEDP in group D and group T increased (P <0.01), dp / dtmax decreased (P <0.05) and HGF increased (P <0.01) <0.01), - dp / dtmax increased (P <0.05), and HGF increased (P <0.01). Conclusion: Telmisartan protects the myocardium of diabetic rats, which may be related to the increase of cardiac HGF.